CA2353776A1 - Composition et procedes de regulation du poids corporel et des pathologies associees - Google Patents

Composition et procedes de regulation du poids corporel et des pathologies associees Download PDF

Info

Publication number
CA2353776A1
CA2353776A1 CA002353776A CA2353776A CA2353776A1 CA 2353776 A1 CA2353776 A1 CA 2353776A1 CA 002353776 A CA002353776 A CA 002353776A CA 2353776 A CA2353776 A CA 2353776A CA 2353776 A1 CA2353776 A1 CA 2353776A1
Authority
CA
Canada
Prior art keywords
animal
compound
pomc
body weight
melanocortin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002353776A
Other languages
English (en)
Inventor
Miles B. Brennan
Ute Hochgeschwender
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roosevelt Eleanor Institute for Cancer Research Inc
Oklahoma Medical Research Foundation
Original Assignee
Eleanor Roosevelt Institute
Miles B. Brennan
Ute Hochgeschwender
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/374,827 external-priority patent/US6603058B1/en
Application filed by Eleanor Roosevelt Institute, Miles B. Brennan, Ute Hochgeschwender, Oklahoma Medical Research Foundation filed Critical Eleanor Roosevelt Institute
Publication of CA2353776A1 publication Critical patent/CA2353776A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002353776A 1998-12-09 1999-12-09 Composition et procedes de regulation du poids corporel et des pathologies associees Abandoned CA2353776A1 (fr)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US11158198P 1998-12-09 1998-12-09
US60/111,581 1998-12-09
US14630499P 1999-07-29 1999-07-29
US14630699P 1999-07-29 1999-07-29
US14630599P 1999-07-29 1999-07-29
US14630199P 1999-07-29 1999-07-29
US14630399P 1999-07-29 1999-07-29
US14629999P 1999-07-29 1999-07-29
US14630099P 1999-07-29 1999-07-29
US14630299P 1999-07-29 1999-07-29
US60/146,299 1999-07-29
US60/146,303 1999-07-29
US60/146,305 1999-07-29
US60/146,300 1999-07-29
US60/146,302 1999-07-29
US60/146,306 1999-07-29
US60/146,304 1999-07-29
US60/146,301 1999-07-29
US09/374,827 US6603058B1 (en) 1998-12-09 1999-08-12 Non-human animal model for obesity and uses thereof
US09/374,827 1999-08-12
PCT/US1999/029337 WO2000033658A1 (fr) 1998-12-09 1999-12-09 Composition et procedes de regulation du poids corporel et des pathologies associees

Publications (1)

Publication Number Publication Date
CA2353776A1 true CA2353776A1 (fr) 2000-06-15

Family

ID=27581011

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002353776A Abandoned CA2353776A1 (fr) 1998-12-09 1999-12-09 Composition et procedes de regulation du poids corporel et des pathologies associees

Country Status (6)

Country Link
EP (1) EP1137340A4 (fr)
JP (1) JP2003520015A (fr)
AU (1) AU3117600A (fr)
CA (1) CA2353776A1 (fr)
MX (1) MXPA01005818A (fr)
WO (1) WO2000033658A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2406755A1 (fr) * 2000-04-28 2001-11-08 Zengen Inc. Systeme et procede de therapie genique utilisant alpha-msh et ses derives
EP1303625A2 (fr) 2000-07-14 2003-04-23 Zycos Inc. Composes en rapport avec alpha-msh et methodes d'utilisation
EP1322954A4 (fr) * 2000-09-13 2005-08-03 Eleanor Roosevelt Inst Procede de traitement de la resistance a l'insuline dans l'obesite et le diabete
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
JP2006527773A (ja) * 2003-06-19 2006-12-07 イーライ リリー アンド カンパニー メラノコルチン受容体４（ｍｃ４）作用薬とその用途
US20060293223A1 (en) * 2003-06-19 2006-12-28 Eli Lilly And Company Patent Division Uses of melanocortin-3 receptor (mc3r) agonist peptides
FR2857873B1 (fr) * 2003-07-21 2006-02-24 Courtage Et De Diffusion Codif Procede et produit cosmetique destines a limiter la croissance des tissus adipeux
EP1732586A1 (fr) * 2004-03-29 2006-12-20 Eli Lilly And Company Utilisations de peptides agonistes du recepteur de la melanocortine 4 (mc4r) administres par perfusion continue
BRPI0508787A (pt) * 2004-04-08 2007-09-04 Astellas Pharma Inc composto ws727713, cepa de actinomiceto, composto com atividade moduladora de receptor de melanocortina, processo para produzir o composto ws727713, modulador de receptor de melanocortina, uso do composto e composição farmacêutica
WO2005118573A1 (fr) 2004-05-28 2005-12-15 Smithkline Beecham Corporation Nouveaux composes de diazepine utilises comme ligands des recepteurs 1 et/ou 4 de la melanocortine
US7169773B2 (en) 2004-07-01 2007-01-30 Smithkline Beecham Corporation Compounds
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
PL1812046T3 (pl) * 2004-10-25 2011-08-31 Centocor Ortho Biotech Inc Przeciwciała naśladowcze wiążące receptor melanokortyny, kompozycje, sposoby i zastosowania
WO2006073771A2 (fr) * 2005-01-05 2006-07-13 Eli Lilly And Company Peptides d'agonistes mc4r ou mc3r lies au polyethyleneglycol
US7790671B2 (en) 2005-10-07 2010-09-07 Codman & Shurtleff, Inc. Implantable pump for protein delivery for obesity control by drug infusion into the brain
AU2009248914A1 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for Treating Neurodegenerative Disorders Related to Neurofibrillary Tangles
CA2742600A1 (fr) 2008-11-04 2010-05-14 Nikolaos Tezapsidis Compositions a base de leptine et methodes de traitement de troubles evolutifs de la fonction cognitive provoques par une accumulation d'enchevetrements neurofibrillaires et de beta-amyloide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100048A (en) * 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight

Also Published As

Publication number Publication date
EP1137340A1 (fr) 2001-10-04
JP2003520015A (ja) 2003-07-02
AU3117600A (en) 2000-06-26
EP1137340A4 (fr) 2005-12-21
MXPA01005818A (es) 2003-07-21
WO2000033658A1 (fr) 2000-06-15

Similar Documents

Publication Publication Date Title
US20060063708A1 (en) Composition and method for regulation of body weight and associated conditions
US20030144174A1 (en) Methods for identifying compounds useful for the regulation of body weight and associated conditions
Tao The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology
Tschöp et al. Rodent obesity models: an overview
US7186694B2 (en) Leptin-related peptides
CA2353776A1 (fr) Composition et procedes de regulation du poids corporel et des pathologies associees
US7790683B2 (en) Leptin-related peptides
US6689938B2 (en) Method for treatment of insulin resistance in obesity and diabetes
WO2004039832A2 (fr) Peptides associes a la leptine
CA2475273A1 (fr) Developpement modifie de l'hypophyse chez la progeniture de femelles animales portantes traitees par la therapie hormonale de liberation de l'hormone de croissance
Tao Mutations in melanocortin-4 receptor: From fish to men
Hsiung et al. A novel and selective β-melanocyte-stimulating hormone-derived peptide agonist for melanocortin 4 receptor potently decreased food intake and body weight gain in diet-induced obese rats
CN101505786A (zh) 涉及能量内稳态的新肽
US6603058B1 (en) Non-human animal model for obesity and uses thereof
US7084242B2 (en) DNA molecule encoding a mutant prepro-neuropeptide Y, a mutant signal peptide, and uses thereof
Fang et al. Development of a transgenic mouse that overexpresses a novel product of the growth hormone-releasing hormone gene
WO2001072119A2 (fr) Modele animal non-humain permettant d'etudier la croissance insuffisante et le traitement de l'information ou les anomalies de la fonction cognitive et utilisation de ce modele
US20120079613A1 (en) Homeobox Transcription Factor BSX and Uses Thereof for Treating Diseases, in Particular Obesity
Ersoy Deciphering the melanocortin system: Three distinct approaches
BRPI9508596B1 (pt) polipeptídeos de obesidade (ob), composição compreendendo os mesmos, bem como vetores para expressão dos referidos polipeptídeos

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead